10-QHealthcare

Dexcom, Inc.

DXCM · Period ending 2026-09-30 · Filed 2026-10-29 · Updated

In short

Dexcom, Inc. (DXCM) has revenue up 15.6% to $4.7B and net income up 45.1% to $836.3M year on year. Its net margin is 17.9% and gross margin 60.1%, and it trades at 34.8× trailing earnings. Fisclear found no medium- or high-severity risk flags in this filing. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$79.32

P/E (TTM)

31.2x

Price ÷ earnings per share

P/B

11.7x

Price ÷ book value

P/S (TTM)

5.8x

Price ÷ revenue per share

Beta

1.44

Moderate market correlation

PEG Ratio

1.3x

P/E ÷ earnings growth rate

52-Week Range

$56.72$79.32 now$92.59

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

DXCM vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — DXCM

Inflationary Boom
✦

Strengths

  • EPS (Diluted): $2.09 (+47.2% YoY) — Earnings per share rose 47% — each share earned more.

  • Operating Cash Flow: $1.4B (+45.6% YoY) — Operating cash flow grew 46% — the business generated more cash from day-to-day operations.

  • Net Income: $836.3M (+45.1% YoY) — Profit grew 45% — the company kept more of each dollar earned.

  • Revenue: $4.7B (+15.6% YoY) — Revenue grew 16% — the company sold more goods or services than the prior year.

  • Gross Profit: $2.8B (+14.9% YoY) — Gross profit rose 15% — the spread between revenue and direct costs improved.

◈

Weaknesses

No material weaknesses flagged.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

No significant threats flagged.

Year-over-Year Changes

EPS (Diluted)

$2.09

was $1.42

+47.2%

Earnings per share rose 47% — each share earned more.

Operating Cash Flow

$1.4B

was $989.5M

+45.6%

Operating cash flow grew 46% — the business generated more cash from day-to-day operations.

Net Income

$836.3M

was $576.2M

+45.1%

Profit grew 45% — the company kept more of each dollar earned.

Revenue

$4.7B

was $4.0B

+15.6%

Revenue grew 16% — the company sold more goods or services than the prior year.

Gross Profit

$2.8B

was $2.4B

+14.9%

Gross profit rose 15% — the spread between revenue and direct costs improved.

Technical Signals

Daily closes · 1-year data

Dexcom, Inc.: common questions

Is Dexcom, Inc. profitable?

Yes. Dexcom, Inc. made a net profit of $836M in its latest fiscal year (fiscal 2025), a net margin of 17.9%.

Is Dexcom, Inc.'s revenue growing?

Yes. Revenue grew 15.6% year on year, to $4.7B.

What is Dexcom, Inc.'s P/E ratio?

Dexcom, Inc. trades at 31.2× its trailing twelve-month earnings. In other words, the share price is about 31 times the profit per share the company earned over the past year.

Does Dexcom, Inc. pay a dividend?

No dividend is currently expected from Dexcom, Inc., according to the latest market data.

Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — DXCM

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade DXCM

Links open broker research pages. Not an endorsement or recommendation.

Research Dexcom, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.